Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
IDEAYA Biosciences ( (IDYA) ) has provided an update.
On August 29, 2025, IDEAYA Biosciences entered into a License Agreement with Les Laboratoires Servier, granting Servier exclusive rights to develop and commercialize darovasertib outside the United States. This agreement includes an upfront payment of $210 million to IDEAYA, with potential additional milestone payments and royalties, extending the company’s cash runway by at least twelve months and funding operations into 2030. The agreement outlines conditions for termination and includes customary transaction provisions.
The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
IDEAYA Biosciences has a moderate overall score primarily driven by strong technical momentum despite significant financial challenges. The lack of profitability and negative cash flows weigh heavily on the valuation, but positive market trends provide a short-term boost.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
IDEAYA Biosciences, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative therapeutics for cancer treatment. The company specializes in precision medicine and small molecule therapies, aiming to address unmet medical needs in oncology.
Average Trading Volume: 990,413
Technical Sentiment Signal: Buy
Current Market Cap: $2.15B
For a thorough assessment of IDYA stock, go to TipRanks’ Stock Analysis page.